Lynch syndrome-associated breast cancers: Clinicopathologic characteristics of a case series from the colon cancer family registry by Walsh, Michael et al.
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Walsh, M.D., Buchanan, D.D., Cummings, M.C., Pearson, S.A., Arnold,
S.T., Clendenning, M., Walters, R., McKeone, D.M., Spurdle, A.B., Hop-
per, J.L., Jenkins, M.A., Phillips, K.D., Suthers, G.K., George, J., Goldblatt,
J., Muir, A., Tucker, K., Pelzer, E., Gattas, M.R., Woodall, S., Parry, S.,
Macrae, F.A., Haile, R.W., Baron, J.A., Potter, J.D., Le Marchand, L., Bapat,
B., Thibodeau, S.N., Lindor, N.M., McGuckin, M.A., & Young, J.P. (2010)
Lynch syndrome-associated breast cancers: clinicopathologic characteris-
tics of a case series from the colon cancer family registry. Clinical Cancer
Research, 16(7), pp. 2214-2224.
This file was downloaded from: http://eprints.qut.edu.au/56555/
c© Copyright 2010 American Association for Cancer Research
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
http://dx.doi.org/10.1158/1078-0432.CCR-09-3058
Lynch Syndrome-Associated Breast Cancers: Clinicopathological
Characteristics of a Case Series from the Colon CFR
Michael D Walsh1,2,#, Daniel D Buchanan1,2, Margaret C Cummings3, Sally-Ann Pearson1,
Sven T Arnold1, Mark Clendenning1, Rhiannon Walters1, Diane M McKeone1, Amanda B
Spurdle4, John L Hopper5, Mark A Jenkins5, Kerry D Phillips6, Graeme K Suthers6,7, Jill
George8, Jack Goldblatt8,9, Amanda Muir10, Kathy Tucker10, Elise Pelzer11, Michael R
Gattas11, Sonja Woodall12, Susan Parry12,13, Finlay A Macrae14, Robert W Haile15, John A
Baron16, John D Potter17, Loic Le Marchand18, Bharati Bapat19, Stephen N Thibodeau20,
Noralane M Lindor20, Michael A McGuckin21, and Joanne P Young1,2
1Familial Cancer Laboratory, Queensland Institute of Medical Research, Herston QLD, Australia
2University of Queensland School of Medicine, Herston, QLD, Australia 3University of Queensland
Centre for Clinical Research, Herston, QLD, Australia 4Molecular Cancer Epidemiology Laboratory,
Queensland Institute of Medical Research, Herston QLD, Australia 5University of Melbourne, Centre
for MEGA Epidemiology, School of Population Health, Melbourne, VIC, Australia 6South Australian
Clinical Genetics Service, North Adelaide, SA, Australia 7Department of Paediatrics, University of
Adelaide, SA, Australia 8Genetic Services of Western Australia, King Edward Memorial Hospital,
Subiaco, WA, Australia 9School of Paediatrics and Child Health University of Western Australia,
Nedlands, WA, Australia 10Clinical Genetics Service, Prince of Wales Hospital, Randwick, NSW,
Australia 11Genetic Health Queensland, Royal Brisbane and Women’s Hospital, Herston, QLD,
Australia 12Northern Regional Genetics, Auckland Hospital, Auckland, New Zealand 13University of
Auckland, Auckland, New Zealand 14Department of Colorectal Medicine and Genetics, The Royal
Melbourne Hospital, Parkville, VIC, Australia 15Keck School of Medicine, University of Southern
California, Los Angeles, CA, USA 16Dartmouth Medical School, Hanover, NH, USA 17Fred
Hutchinson Cancer Research Center, Seattle, WA, USA 18Cancer Research Center of Hawaii,
University of Hawaii at Manoa, Honolulu, HI, USA 19Samuel Lunenfeld Research Institute, Mount
Sinai Hospital, University of Toronto, Toronto, Canada 20Mayo Clinic, Rochester, MN, USA 21Mater
Medical Research Institute, South Brisbane, QLD, Australia
Abstract
PURPOSE—The recognition of breast cancer (BC) as a spectrum tumor in Lynch syndrome remains
controversial. The aim of this study was to explore features of breast cancers arising in Lynch
syndrome families.
EXPERIMENTAL DESIGN—This observational study involved 107 cases of BC identified from
the Colorectal Cancer Family Registry (Colon CFR) from 90 families where 1) both breast and colon
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cancer co-occurred, 2) families met either modified Amsterdam criteria, or had at least one early
onset (<50 years) colorectal cancer, and 3) breast tissue was available within the biospecimen
repository for mismatch repair (MMR) testing. Eligibility criteria for enrolment in the Colon CFR
are available online1. Breast cancers were reviewed by one pathologist. Tumor sections were stained
for MLH1, PMS2, MSH2 and MSH6, and underwent MSI testing.
RESULTS—BC arose in 35 mutation carriers and of these, 18 (51%) demonstrated
immunohistochemical absence of MMR protein corresponding to the MMR gene mutation
segregating in the family. MMR-deficient BCs were more likely to be poorly differentiated (p=0.005)
with a high mitotic index (p=0.002), steroid hormone receptor negative (ER p=0.031; PR p=0.022),
and to have peritumoral lymphocytes (p=0.015), confluent necrosis (p=0.002), and growth in solid
sheets (p<0.001) similar to their colorectal counterparts. No difference in age of onset was noted
between the MMR deficient and intact groups.
CONCLUSIONS—MMR deficiency was identified in 51% of BC arising in known mutation
carriers. BC therefore may represent a valid tissue option for the detection of MMR deficiency where
spectrum tumors are lacking.
Introduction
Defects in autosomal dominant genes are suspected to be responsible for up to 10% of all breast
cancers (BCs) (1;2). The most commonly affected known genes are BRCA1 and BRCA2 while
other genes such as p53, PTEN, STK11/LKB1 and CDH1 are implicated in fewer cases (3;4).
There are, in addition, a significant number of cases of breast cancer that present at an earlier
than usual age of onset and with a conspicuous family history for which the causative gene(s)
has not been identified (5).
Lynch syndrome, or hereditary non-polyposis colorectal cancer (HNPCC) (6), was first
identified nearly a century ago as familial clustering of cancers, particularly of the colon, small
intestine, stomach, endometrium, upper urinary tract and sebaceous tumors of the skin.
Approximately 80 % of Lynch-syndrome associated cancers are attributable to defects in the
DNA mismatch repair (MMR) genes MLH1 and MSH2, with the majority of the remaining
cases occurring in carriers of mutations in MSH6 and, to a lesser extent, PMS2 (7). The
consideration of breast cancer as a spectrum tumor in Lynch syndrome has been controversial
with evidence for and against constituting a rigorous debate over time. An extensive study
published in 2002 excluded breast cancer as part of the Lynch syndrome spectrum of tumors
(8). Another study, whilst demonstrating no increased risk for developing mammary cancers
found that tumors in known carriers presented at an earlier age (9). This led de Leeuw et al to
postulate that, whilst MMR deficiency does not in itself initiate breast tumors, the increased
rate of mutation accelerates their progress leading to an earlier presentation (10). In contrast
to these observations, Scott et al reported a significant 15-fold increased risk of breast cancer
in MLH1 mutation carriers (but not MSH2 carriers) (11), and a study of Brazilian Lynch
syndrome families showed an increased incidence of breast cancer equal in incidence to
endometrial cancer cases (12), though this study used clinical criteria to define Lynch
syndrome. In more recent times, both case reports (13;14) and statistical studies (15;16)
respectively have shown that MMR-deficient breast cancers can and do arise in mutation
carriers.
Immunohistochemistry (IHC) screening of tumors for deficiency in MMR proteins is currently
the most efficacious method for the recognition of Lynch syndrome (17). IHC allows not only
identification of potential Lynch syndrome patients, but also by its pattern of staining, the most
likely causative gene. This is important because tracking down a mutation in MMR genes is
not a trivial exercise. IHC is generally applied to recognized Lynch syndrome spectrum tumors
such as those from the colorectum, endometrium, ovary, stomach and urothelial tissues. This
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has also become increasingly important as family size decreases and screening becomes more
widespread, lessening the power of clinical criteria to detect Lynch syndrome, and highlighting
the need to increase the potential sources of tissue that may be utilized for diagnosis. Breast
cancers with both MSI and/or immunohistochemical absence of MMR proteins have been
reported by many authors (13;14;18–23), though many of these reports contain small numbers
of cases. In this study, we sought to establish the frequency with which breast cancers occurring
in mutation carriers for Lynch syndrome display microsatellite instability as a consequence of
loss of DNA MMR proteins, and to examine the clinicopathological features of such tumors.
This study represents the largest series of breast cancers with MMR deficiency reported to
date, and attests to the utility of breast tissue as a diagnostic sample in suspected Lynch
syndrome when colon or endometrial tissue is unavailable (13).
Patients and Methods
Patients
One hundred and seven cases of breast cancer (arising in 102 females and 2 males) from 90
colorectal cancer families were identified from the Colorectal Cancer Family Registry (Colon
CFR), a National Cancer Institute–supported consortium established in 1997 to create a
comprehensive collaborative infrastructure for interdisciplinary studies of the genetic and
molecular epidemiology of colorectal cancer (see detailed information about the registry at the
CFR website2) (24). All patients in this study had institutional review board approval under
the policies and procedures of the Colon CFR for recruitment of participants and protocols for
carrying out research projects. The average age of patients with breast cancer was 56.1 ± 11.3
years, ranging from 36.1 to 86.7 years of age.
Families were selected for study in which 1) both breast and colon cancer co-occurred, with
at least one breast cancer regardless of age at diagnosis 2) families met either modified
Amsterdam criteria, or had at least one early onset (<50 years) colorectal cancer, and 3) breast
tissue was available within the biospecimen repository for mismatch repair (MMR) testing
thereby limiting the number of families which could be analysed. Comprehensive cancer
histories and tissue were available for 90 families recruited through the Australasian Colorectal
Family Registry and the Mayo Clinic Cooperative Family Registry for Colon Cancer Studies.
The majority of families (n=86) were enrolled in the Colon CFR on the basis of a strong family
history of colorectal cancers compatible with Lynch syndrome, and the remaining four families
were identified following enrollment of participants with early onset (<50 years) colorectal
cancer.
Fifty-four of ninety (60%) families met modified Amsterdam criteria, and the remainder had
multiple cancers including at least one early onset (<50 years) colorectal cancer per family. In
13 cases (13%) the breast cancer patient was also affected with early onset colorectal cancer,
58 individuals (56%) were first degree relatives of an individual with early onset CRC, 25
individuals (24%) were second degree relatives, and the remaining 8 cases (8%) were more
distantly related. All reported tumors (breast and other sites) were verified by either
examination of the original histopathology material or histopathology reports for all affected
kindred members where possible. In three cases, bilateral metachronous tumors were available
for testing. In no instances was there evidence of familial adenomatous polyposis (FAP). No
deleterious mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 were
detected in the small minority of families (n = 7) tested. As the Colon CFR recruits families
on the basis of CRC, it is unlikely that families enrolled in this registry would be of the type
of configuration that would trigger BRCA1 testing.
2http://epi.grants.cancer.gov/CFR
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Histopathological Review
One consultant histopathologist (MCC) reviewed material from 104 of the 107 cases of breast
cancer to confirm diagnosis and score histopathological features. Clinicopathological data for
the remaining three cases was abstracted from histopathology reports. Note was made of the
following features: tumor location, size, primary histological type, tumor grade (using the
Nottingham modification of Bloom Richardson system (25)), tumor margin, confluent
necrosis, calcification, presence of tumor infiltrating and peritumoral lymphocytes, presence
of in situ carcinoma and atypical ductal hyperplasia and axillary lymph node status. While note
was also made of the steroid hormone receptor status as originally reported, these markers were
reassessed by immunohistochemistry in our laboratory owing to the large number of
incomplete reports. HER2/neu status was extracted, where available, from original laboratory
reports.
Immunohistochemistry
for DNA mismatch repair proteins was performed as previously described (26). A subset of
tumors was stained for ER and PR, and p53. Paraffin sections (4µm) were subjected to heat
induced epitope retrieval in High pH Target Retrieval Solution (Dako Corporation, Carpinteria,
CA) for ER and PR, and Reveal Decloaker solution™ (BioCare Medical, Concord, CA) for
p53. Sections were stained with rabbit monoclonal anti-human ER (clone SP1) or rabbit
monoclonal anti-human PR (clone SP2) at 1/2500 or mouse monoclonal anti-p53 antibody at
1/100 followed by the EnVision Plus Mouse HRP detection system (Dako) for p53, or MACH3
Rabbit HRP polymer kit (BioCare Medical) for ER and PR. The proportion of positive cancer
cell staining was graded as follows: 0 (negative), less than 10% (1+), 11–25% (2+), 26–50%
(3+), 51–75% (4+) and more than 75% (5+). Tumors were scored as positive where there was
strong expression in >10% tumor cells. Histologically normal breast epithelium present within
tumor blocks served as the positive control for ER and PR, and sections from known p53-
overexpressing colorectal cancers as the positive control when staining for p53 in breast
cancers.
Assessment of Tumors for Microsatellite Instability and MLH1 Methylation
Tumors were assessed for microsatellite instability using a panel of 10 microsatellite markers
and classified as MSI-H (MSI high) if ≥ 30% of the markers showed instability, MSI-L (MSI
low) if one or more markers but < 30% of all markers demonstrated instability and MSS
(microsatellite stable) if no marker exhibited instability as has been previously reported (17).
Only cases with 5 or more evaluable markers were considered. Methylation of the MLH1
promoter was detected using the Methylight assay as has been recently described (27).
BRAF V600E Allele Specific PCR Assay
The somatic T>A mutation at nucleotide 1799 causing the V600E mutation in the BRAF gene
was determined using a fluorescent allele specific PCR assay. Briefly, 20–50ng of DNA,
extracted from formalin-fixed paraffin embedded tumour tissue, was amplified in a 25µl
reaction containing 100nM each of allele specific primers tagged with differing fluorophores
(Mutant Primer (F1): 6-Fam-5’-CAGTGATTTTGGTCTAGCTTCAGA-3’ Wild Type Primer
(F2): NED - 5’- TGATTTTGGTCTAGCTACAGT-3’ and a common reverse primer (Reverse
Primer (REV): 5’-CTCAATTCTTACCATCCACAAAATG-3’), together with 2.5units of Taq
polymerase (Eppendorf), 1x buffer and 200µM of dNTPs. The cycling conditions consisted of
an initial denaturation of 95°C for 2mins followed by 35 cycles of 94°C for 30sec, 59°C for
30sec and 65°C for 30sec then a final extension of 65°C for 10mins. After amplification 1µl
of the PCR product was added to an 8.7µl mix of HiDi formamide and ROX Genescan 500
size marker (Applied Biosystems, Foster City, CA). The mutant allele (A1799) primer
generated a PCR product of 97bp, 3bp larger than the wildtype PCR product after separation
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on an ABI 3100 genetic analyser. GeneMarker (SoftGenetics) software was used to identify
the different size and fluorescent allele PCR products. Positive and negative controls were run
in each experiment and 10% of samples were replicated with 100% concordance.
Mutation Testing
DNA (10ng) was amplified in 25µl reactions using HotMaster Taq and buffer (Eppendorf,
Hamberg, Germany) with 20pmol of each primer. Cycling protocols were applied according
to previously established conditions for each primer set and amplicon, verified to selectively
amplify the target amplicon only. PCR products were cleaned using Millipore Montage PCR96
Cleanup Plates (Millipore, Bedford, MA, USA). Cleaned PCR product (1µl) was used in a
12µl sequencing reaction utilizing the BigDye Terminator v3.1 reagents and protocol (Applied
Biosystems, Foster City, CA, USA) and 2pmol of primer. Sequencing product was cleaned
with the DyeEx 96 Kit (Qiagen, Hilden, Germany) using the recommended protocol. The
product was dried, resuspended in HiDi Formamide (Applied Biosystems, Foster City, CA,
USA) and analyzed on an ABI PRISM 3100 (Applied Biosystems, Foster City, CA, USA). Bi-
directional sequencing was performed throughout. Results were compared to reference
sequence NC_000003.10 (genomic) and NM_000249.2 (cDNA) for MLH1, and
NC_000002.10 (genomic) and NM_000251.1 (cDNA) for MSH2, NC_000002.11 (genomic)
and NM_000179.2 (cDNA) for MSH6, and NC_000007.13 (genomic) and NM_000535.3
(cDNA) for PMS2. MLPA was used to detect large exonic deletions and duplications in the
four MMR genes, using the Salsa MLPA P003 and P248 kits for MLH1 and MSH2 and the
P008 kit for MSH6 and PMS2 (MRC-Holland, Amsterdam, The Netherlands) according to
manufacturer’s protocol.
Statistical Analysis
was carried out using Statistical Package for Social Sciences (SPSS, version 17.0).
Contingency tables were assessed using Chi-squared or Fisher’s exact test as appropriate.
Differences between means were assessed using a t-test after testing to ensure equality of the
variance in groups using probability plots and an F-test. P values < 0.05 were considered
significant. Sensitivity and specificity calculations were performed using VassarStats 3.
Results
Of 90 families with breast and colorectal cancer, 53 families (59%) were classified as Lynch
syndrome on the basis of a germline mutation (n=52) or multiple MSH2/MSH6 deficient
tumors within the family (n=1). Table 1 shows the distribution of families amongst the four
causative MMR genes (MLH1, MSH2, MSH6 and PMS2). In thirty-seven remaining families,
Lynch syndrome could be excluded as no evidence of MMR deficiency from IHC or MSI
testing was found, nor were any MMR mutations identified where tested. In 30 families Lynch
syndrome was excluded on the basis of IHC and MSI testing of several family members with
no evidence of MMR deficiency. The remaining seven families showed multiple MLH1-
deficient colorectal and/or endometrial cancers associated with MLH1 methylation and/or
somatic BRAF mutation (CRC only) with no evidence of germline mutations in MLH1 either
by direct sequencing or MLPA. Only one of these seven families met modified Amsterdam
criteria (ACII). None of the 61 breast cancers in this study, which could be analyzed,
demonstrated the V600E activating mutation in BRAF.
Abnormal immunostaining for MMR protein was observed for 18/107 breast cancers (17%)
(Figure 1 and Supplementary Figure 1 and Supplementary Figure 2). In twelve cases, tumors
showed loss of MSH2 and MSH6 proteins, in five cases MLH1 and PMS2 were absent, and
3http://faculty.vassar.edu/lowry/VassarStats.html
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in one case, MSH6 only was absent. Microsatellite instability testing was performed for 89
breast cancers and was concordant with IHC results in 85 cases (96%). All but one of the MMR
deficient breast cancers arose in families meeting ACII. Of the 18 participants whose breast
cancers showed loss of one or more MMR proteins on IHC, 16 tested positive for germline
mutations in the DNA MMR genes MLH1, MSH2 or MSH6 consistent with both their tumor
immunodeficiency as well as their respective family mutation, whilst a further individual who
was deceased was found to be an obligate carrier of her family mutation (Table 2). The
remaining case demonstrating immunohistochemical loss of MSH2 and MSH6 arose in a
family in which no MSH2 mutation has been identified to date but which has three affected
kindred members where their tumors demonstrate commensurate loss of MMR proteins.
Overall, 18/35 known MMR mutation carriers with breast cancer (51%) produced a breast
cancer that was MMR deficient. Of the 89 breast cancers with normal immunohistochemistry,
13 arose in individuals from families where MLH1 mutations were identified, 20 in individuals
with a family MSH2 mutation, 5 with MSH6 mutations and 3 with PMS2. Of these 41, 17
individuals tested carried the family mutation, suggesting that only a proportion of breast
cancers in mutation carriers are associated with MMR deficiency.
Ten of the 18 individuals showing loss of one or more MMR proteins in their breast cancers
had other primary tumors as summarized in Table 3. In three of the ten cases, the breast cancer
was the first diagnosed malignancy, preceding the second cancer by between 2 and 27 years.
In the other patients, the breast cancers were diagnosed between 1 and 42 years after the first
cancer. In all cases but one (a meningioma), the non-breast cancers tested showed the same
pattern of MMR protein deficiency as the breast tumors, a finding which supports the premise
of this report, namely that the breast cancers in mutation carriers that are MMR deficient are
likely to have developed in association with the germline mutation carried. Importantly, in
eight cases of breast cancer in a proven mutation carrier, breast cancer was the only cancer
documented.
There was no statistical difference in age of presentation between the MMR deficient breast
cancers (mean = 57.5 ± 8.1 yr, range 43.4 – 75.0 yr) and MMR intact BCs (mean = 55.8 ± 11.9
yr, range 36.1 – 86.7 yr) (p=0.56), nor between the MMR deficient BC group and MMR intact
known mutation carriers (57.1 ± 12.0 yr, range 36.1 – 80.5 yr) (p=0.90). Similarly, no difference
in mean age of presentation was observed between the five BC cases which were MMR
deficient in MLH1 germline mutation carriers and the twelve cases occurring in MSH2 carriers
(58.0 yr vs. 57.5 yr) (p=0.90). The average age of the 11 individuals with the primary or only
cancer being a breast cancer with MMR deficiency was 53.7 ± 6.0 yr.
In 104 breast cancers that underwent pathology review, histological differences for invasive
BCs only were compared, with twelve cases of ductal carcinoma in situ excluded from analysis.
Specifically, MMR deficient invasive breast cancers (n=16) were more likely to be estrogen-
and progesterone receptor negative (p=0.031 and p=0.022 respectively), have peritumoral
lymphocytes (p=0.015), to have confluent necrosis (p=0.002), to have growth in solid sheets
(p<0.001), and to have a higher mitotic rate (p=0.002) when compared to MMR-proficient BCs
(n=79). In addition, MMR deficient breast cancers less frequently had contiguous in situ disease
(p=0.038). No statistically significant association was seen between MMR status and tumor
type, size, lymphovascular invasion, node status, prominent eosinophilic nucleoli, or tumoral
calcification (Table 4 and Supplementary Table 1). No statistical differences were observed
for clinicopathological features between the MMR-proficient invasive breast tumors arising in
known carriers of germline MMR gene mutations and tumors from the non-Lynch syndrome
group (data not shown), and therefore all MMR-intact tumors were considered together as the
reference group for comparison with MMR-deficient invasive cancers. There were, however,
significant differences in growth in solid sheets (p=0.002), and the presence of pushing margins
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(p=0.042), and confluent necrosis (p=0.017) and residual carcinoma in situ (p=0.004) between
MMR deficient and intact invasive cancers amongst proven carriers of MMR gene germline
mutations (Table 5).
Four tumors displayed typical BRCA1 histological phenotype (characterized by high grade,
high mitotic index, pushing margin, growth in solid sheets, and the presence of lymphocytic
infiltrate and tumor necrosis (28)), and two of these tumors (50%) showed loss of MSH2 and
MSH6.
The two cases of ductal carcinoma in situ which exhibited loss of MMR expression were both
of solid type, but there was no significant difference overall between DCIS type (cribriform,
solid, papillary or clinging) and MMR expression when including in situ disease accompanied
by an invasive component (p = 0.45) (data not shown). Lobular carcinoma in situ was present
in eight cases accompanying invasive disease. There was no statistically significant difference
between MMR deficient and proficient breast cancers and over-expression of p53 (p = 0.39).
There was a trend for individuals with a MMR deficient breast cancer to have also developed
an early onset colorectal cancer, or was a first degree relative of someone so affected (n= 15)
when compared to individuals with a MMR proficient BC having more distantly related cases
of early-onset CRC (n=3) (p=0.11, 21% vs. 9%, respectively). Of the thirteen cases in which
the same individual had both early-onset colorectal cancer and breast cancer, five (39%)
showed mismatch repair deficiency. There was no statistical difference between degree of
kinship between the breast and early onset CRC patients within individual families and whether
the pedigree satisfied the modified Amsterdam criteria (p = 0.17).
Discussion
In the present study we have examined the incidence of mismatch repair deficiency occurring
in breast cancers from families with a history of early onset (<50 yr) colorectal cancer and
breast cancer occurring at any age. Of the 104 individuals investigated, 35 were found to harbor
deleterious mutations in one of the DNA mismatch repair genes, and of these, 18 individuals
(51%) were found to have loss of MMR expression consistent with their respective germline
mutations. This study follows previous reports where several groups have examined breast
cancers with varying panels of markers in order to assess the extent of instability in tumors
from this site. Many, however, have yielded disappointing results where little or no instability
could be detected in the majority of tumors (22;29–32) although these studies were not
specifically designed to detect Lynch syndrome. In 1996, Risinger and colleagues described
breast cancer occurring in Lynch syndrome kindreds that showed high-level microsatellite
instability. On the basis of this, it was suggested that breast cancer might be included in the
tumor spectrum of Lynch Syndrome II (21). A subsequent study failed to show an increased
risk for breast cancer in Lynch syndrome, and further suggested that sporadic breast cancer
with MMR deficiency may be exceedingly rare (8). However, reports of breast cancer with
MMR deficient phenotypes continued to be presented (9;10;33) with more targeted studies
subsequently demonstrating that MSI is indeed a common feature of breast cancers occurring
in known mutation carriers, being found in up to 60% of cases (10;34;35). In our study, where
MSI and IHC results were highly correlated, we returned a figure of 51% for the proportion of
breast cancers (which included a male breast cancer) arising in MMR mutation carriers that
demonstrated MMR deficiency, commensurate with this previously reported figure.
A study by Vasen and co-workers of 200 putative Lynch syndrome families has shown that
though breast cancer occurs at an early age in Lynch syndrome, there is no elevated risk per
se (9). This suggested that MMR deficiency may accelerate tumorigenesis in breast cancers
which occur in Lynch syndrome mutation carriers but is unlikely to be the initiating event
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(10). We found no significant difference between MMR proficient and MMR deficient breast
cancers when age of onset was analyzed. The mean age at diagnosis was 57 years in our study.
Vasen et al. reported a mean age of 46 years for seven cases of breast cancer arising in mutation
carriers (9), or 50 years reported by both Stupart et al. who examined incidence of breast cancers
in women carrying in common a single mutation in MLH1 (c. C1528T)(36) and Jensen et al.
for a series of breast cancers arising in 20 mutation carriers reported recently (35). The numbers
of cases in all studies are, however, small, and recruitment biases in different studies may
account for any differences.
Medullary carcinomas of the breast show morphological similarities to the MSI-high colorectal
tumors (poor differentiation and lymphocytic infiltrate) and a proportion of these are MSI-high
(37). Many of the studies to date investigating the issue of breast carcinomas arising in the
setting of Lynch syndrome have been anecdotal case reports of one or two patients who have
shown loss of appropriate MMR proteins by immunohistochemistry and/or high levels of
microsatellite instability in tumors arising in proven mutation carriers (19;38;39). With such
small numbers in any given study, it has been difficult to determine whether there is an “MSI”
phenotype associated with such cancers, although Yee et al described higher levels of MSI in
lobular carcinomas (39%) than in infiltrating ductal cancers (13.5%) (40). The issue has been
made all the more difficult in that, whilst some breast cancers in mutation carriers have
appropriate MMR protein loss with resultant MSI, there are commensurate numbers of reports
of breast tumors arising in proven carriers which have competent MMR (8;39;41). In this
report, we found that breast cancers with proven MMR deficiency are significantly more likely
than those with proficient MMR to demonstrate hormone receptor negativity, poor
differentiation, a solid growth pattern, lymphocytic infiltrate, high mitotic rate, confluent
necrosis and vesicular tumor nuclei. In common with the study by Jensen et al., we found that
ductal carcinoma NOS was the predominant histotype (35) with no evidence of over-
representation of specific types such as medullary or invasive lobular carcinoma.
Several of these features including poor differentiation and lymphocytic infiltrate are also
reported features of Lynch syndrome colorectal cancers (42;43), and a dense lymphocytic
infiltrate has been previously shown in a breast cancer case arising in a Lynch syndrome
mutation carrier (14), and more recently in a larger series of MMR deficient BCs arising in
mutation carriers where half of the six tumors were reported to have both TILs and PTLs
(35).
The presence of breast cancer in Lynch syndrome has been reported to be over-represented in
Lynch syndrome families with MLH1 mutations (11;15). Rarer causes of Lynch syndrome
such as germ line mutations in MSH6 have also been associated with synchronous breast and
colon cancers (44). However, due to our limited study design, we are unable to offer any
comments regarding whether or not the risk of breast cancer is increased in Lynch syndrome
mutation carriers.
Familial aggregation of cancers from different anatomical sites has been previously
documented (45–47). Such clustering may arise from shared environmental risk factors
common to the cancers, inherited defects in cancer susceptibility genes or interaction between
the two. A series of large studies utilizing the Swedish Family-Cancer Database, concluded
that in the absence of known, strong environmental risk factors, most of the familial aggregation
that is observed is likely due to genetic factors that increase the risk of cancer at more than one
site (48). In addition, it has become increasingly apparent that most inherited cancer
susceptibilities confer a risk for cancer at a range of sites, suggesting that mechanisms of
carcinogenesis are shared by different tissues. This is true of Lynch syndrome, where a defect
in DNA MMR clearly confers an increased risk for cancers of the colorectum, endometrium,
ovary, stomach, bladder and renal pelvis. As described in multiple previous reports, we found
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gene-appropriate MMR deficiency to be also readily demonstrable in approximately half of
the breast cancers arising in Lynch syndrome mutation carriers using MMR protein
immunohistochemistry, thereby confirming breast cancer tissue as a valid screening option for
Lynch syndrome diagnosis. A caveat to testing breast cancers for Lynch syndrome however is
that, whilst in this study we demonstrated that loss of MMR by IHC is 100% specific for Lynch
syndrome, the sensitivity for detecting a mutation carrier is only 51.4%. This compares with
a much higher sensitivity for colorectal cancers where MMR proficient phenocopies are
relatively rare in mutation carriers.
Further, we found that MMR deficient tumors demonstrate certain histological features
significantly more often than would be expected thus increasing confidence in the selection
and use of particular breast cancers for this purpose. It is worth noting that, of four cancers that
displayed the “BRCA1” histological phenotype, two showed loss of MMR proteins suggesting
that screening of such cases for Lynch syndrome might be considered where BRCA1 mutation
testing has proved fruitless. The finding that breast carcinoma was the only malignancy
reported for half of the women with MMR deficient BCs is consistent with the findings of
Jensen et al. who reported no other cancer types in three of seven such cases (35).
Translational Relevance
Lynch syndrome predisposes individuals to increased rates of colorectal and endometrial
cancer. Lynch syndrome tumors are characterized by loss of DNA mismatch repair proteins,
and it is this feature which can be used for recognition of Lynch syndrome amongst incident
cancers in a population. Whether breast cancers constitute part of the tumor spectrum in
this syndrome, and thus could be used for molecular diagnosis of Lynch syndrome, remains
controversial. In this report, we demonstrate that not only do 50% of breast cancers arising
in Lynch syndrome mutation carriers show loss of mismatch repair proteins, but also, that
they have histological features which further alert pathologists to the possibility that a breast
cancer may be arising in a person who has Lynch syndrome. With families becoming smaller
the addition of breast cancer to the repertoire of tissues which can be used to identify patients
and families at risk is likely to improve detection rates.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
(A) – (D) illustrate a poorly differentiated ductal carcinoma showing retention of MLH1 (A)
and PMS2 (D) expression but loss of MSH2 (B) and MSH6 (C) staining in tumor cells.
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Table 2
Mutation status of individuals with MMR deficient breast cancers
Individual Sex IHC absent Family mutation Individual
status
FN4770-02 F MLH1 and PMS2 MLH1: c.76C>T p.G26X POSITIVE
FN2100-09 M MLH1 and PMS2 MLH1: c.1946delC p.P649fs POSITIVE
FN3321-01 F MLH1 and PMS2 MLH1: c.1954G>T p.G652X POSITIVE
FN3321-10 F MLH1 and PMS2 MLH1: c.1954G>T p.G652X POSITIVE
FN1120-34 F MLH1 and PMS2 MLH1: c.350C>T p.T117M POSITIVE
FN1710-01 F MSH2 & MSH6 Not found *
FN5122-12 F MSH2 and MSH6 MSH2 del x2-8 POSITIVE
FN6930-01 F MSH2 and MSH6 MSH2: dup x9-11 POSITIVE
FN4340-01 F MSH2 and MSH6 MSH2: c.508C>T p.Q170X POSITIVE
FN1750-01 F MSH2 and MSH6 MSH2: c.685A>T p.K229X POSITIVE
FN1010-16 F MSH2 and MSH6 MSH2: c.892C>T p.G298X POSITIVE
FN1601-01 F MSH2 and MSH6 MSH2: c.892C>T p.Q298X POSITIVE
FN7310-02 F MSH2 and MSH6 MSH2: c.545+1G>A r.spl. POSITIVE#
FN4610-14 F MSH2 and MSH6 MSH2: c.1165C>T p.R389X POSITIVE
FN5055-01 F MSH2 and MSH6 MSH2:c.1704_5delAG
p.Glu569IlefsX2
POSITIVE
FN3992-11 F MSH2 and MSH6 MSH2: c.2038C>T p.R680X POSITIVE
FN6003-02 F MSH2 and MSH6 MSH2:
c.1886_1889delAAGG
p.Gln629fs
POSITIVE
FN4430-01 F MSH6 MSH6:
c.1628_1629delAA p.K543fs
POSITIVE
*
Multiple affected family members with MSH2/MSH6 deficient tumors but no germline mutation found in either MSH2 or MSH6, and also negative
for large rearrangements in EpCAM (TACSTD1)
#
Obligate carrier
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Table 3
Multiple MMR deficient tumors in MMR deficient breast cancer patients
Individual Age (yr) Tumor site MMR IHC
FN1601-01 48 Breast MSH2 and MSH6 absent
75 Meningioma IHC normal
FN1120-34 54 Breast MLH1 and PMS2 absent
58 Endometrial MLH1 and PMS2 absent
60 Colorectal MLH1 and PMS2 absent
64 Stromal sarcoma (post XRT) PMS2 only absent
FN5055-01 49 Breast MSH2 and MSH6 absent
51 Sebaceomas MSH2 and MSH6 absent
52 Endometrial MSH2 and MSH6 absent
FN1750-01 40 Colorectal MSH2 and MSH6 absent
51 Breast #1 MSH2 and MSH6 absent
57 Breast #2 Not tested
FN4610-14 43 Colorectal MSH2 and MSH6 absent
50 Colorectal MSH2 and MSH6 absent
65 Breast MSH2 and MSH6 absent
FN4340-01 55 Colorectal MSH2 and MSH6 absent
56 Breast MSH2 and MSH6 absent
FN4770-02 53 Endometrial MLH1 and PMS2 absent
63 Colorectal MLH1 and PMS2 absent
64 Breast MLH1 and PMS2 absent
FN7310-02 61 Endometrial MSH2 and MSH6 absent
66 Breast MSH2 and MSH6 absent
FN6003-02 52 Colorectal MSH2 and MSH6 absent
55 Endometrial MSH2 absent
64 Breast MSH2 and MSH6 absent
FN5122-12 33 Endometrial Not tested
55 Colorectal Not tested
56 Colorectal Not tested
62 Colorectal Not tested
63 Colorectal MSH2 and MSH6 absent
75 Breast MSH2 and MSH6 absent
75 Bladder MSH2 and MSH6 absent
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